^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Turalio (pexidartinib) (c-KIT inhibitor, FLT3 inhibitor, AKT inhibitor, CSF-1R inhibitor, FMS kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Excerpt:
    ...- Positive for Flt3-ITD activating mutations during Screening....
    Trial ID:
    NCT01349049
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Discov
    Title:

    Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397

    Excerpt:
    We performed proliferation studies of PLX3397 and quizartinib for Ba/F3 cells expressing FLT3-ITD and FLT3-ITD/F691L and confirmed that PLX3397, in contrast with quizartinib, has the ability to inhibit the proliferation of both isoforms...
    DOI:
    10.1158/2159-8290.CD-15-0060